这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 3月4日，拓新药业公告，公司全资子公司精泉生物于近日正式通过了NSF 173 GMP DI认证，标志着公 司已通过NSF严格的质量与安全审核，符合美国联邦法规针对原料生产企业所制定的良好生产规范要 求。 新诺威：艾美赛珠单抗注射液药物临床试验获批 政策动向 市场监管总局进一步加强特殊医学用途配方食品安全监管 市场监管总局近日修订发布《特殊医学用途配方食品生产许可审查细则（2026版）》。《细则》共7章 43条，从生产场所、设备设施、工艺流程、人员管理、制度管理等方面进行严格要求，主要修订了以下 内容：按照2025版特医食品标准的产品分类，调整细化生产许可品种明细；按照2023版特医食品良好生 产规范，进一步明确作业区环境卫生控制要求和关键设备监控要求；按照新修订的《食品生产经营企业 落实食品安全主体责任监督管理规定》，细化关键人员岗位职责；针对产品适用人群及其过敏风险管理 需求，强化产品过敏风险管控；结合出现的食品安全风险以及储运等最新要求，进一步严格原料管理。 3月起，中药将面临最严监管 3月1日起，《中药生产监督 ...

Company News - Bank of China (03988.HK) has completed the issuance of 50 billion yuan in subordinated capital bonds, with the funds intended to supplement the bank's Tier 2 capital, subject to applicable laws and regulatory approvals [2] - Huadian International Power (01071.HK) has fully commissioned two 660,000 kW ultra-supercritical units at the Huadian Longkou Phase IV project, which integrates advanced technologies and achieves energy consumption levels comparable to the best in the domestic market, enhancing grid stability and local heating and industrial steam supply [2] - Weisheng Holdings (03393.HK) has entered into a capital increase agreement with Boyu Capital, with Boyu investing a total of 380 million yuan to subscribe for additional shares in its subsidiary [3] - Green Leaf Pharmaceutical (02186.HK) has granted Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [4] - Heng Rui Medicine (01276.HK) has had its injectable SHR-A1904 included in the list of breakthrough therapy products by the drug review center [5] - Youzhiyou Biotechnology-B (02496.HK) has received IND approval from NMPA for Y225 (Aimeisai monoclonal antibody injection) [6] - MicroPort Robotics-B (02252.HK) has achieved a global commercialization milestone with over 100 installations of its Tumi laparoscopic surgical robot [7] - Gao Shan Enterprises (00616.HK) has signed a memorandum of understanding to establish a joint venture to participate in or invest in stablecoins and blockchain-related industries [8] - Energy International Investment (00353.HK) plans to issue a total of 1.035 billion subscription shares at a discount of approximately 18.33%, aiming to raise about 254 million HKD [9] Buyback Activities - Tencent Holdings (00700.HK) has repurchased approximately 636 million HKD worth of 1.056 million shares at prices ranging from 598 to 604 HKD [10] - Xiaomi Group-W (01810.HK) has spent 149 million HKD to repurchase 3.8 million shares at prices between 39.08 and 39.26 HKD [11] - China COSCO Shipping Holdings (01919.HK) has repurchased shares worth approximately 27.225 million HKD, acquiring 1.96 million shares at prices from 13.82 to 13.95 HKD [12] - Kuaishou-W (01024.HK) has repurchased shares for about 29.9896 million HKD, buying 464,000 shares at prices between 64.05 and 64.9 HKD [13]

Core Viewpoint - Hemophilia is a hereditary bleeding disorder primarily treated through factor replacement therapy, with significant advancements in drug development leading to increased demand and market growth in China [1][6][20]. Industry Definition and Categories - Hemophilia is characterized by a deficiency in clotting factors, leading to prolonged bleeding tendencies, and can be classified into Hemophilia A and B, with A being more prevalent [2][3]. Current Industry Status - The demand for hemophilia drugs is on the rise due to advancements in diagnosis and treatment, with a projected demand of 5.8236 million doses in 2024 and 7.3154 million doses in 2025, reflecting a growing market size from 5.361 billion yuan in 2024 to 5.856 billion yuan in 2025 [6][9]. Market Competition Landscape - Major domestic companies in the hemophilia drug market include Beijing Shenzhou Cell Engineering, Shandong Taibang Biological Products, Henan Hualan Biological Engineering, and Shanghai Raist Blood Products, among others [13][14]. Industry Development Trends - The hemophilia drug industry is expected to benefit from technological innovations and increased awareness, leading to a broader market outlook as more patients can afford treatment and government support for rare diseases grows [20].